Sanofi: end of a test in the Covid-19 in the United States

| |

( – Sanofi and Regeneron Pharmaceuticals announce the discontinuation of the phase III trial of Kevzara (sarilumab) 400 mg conducted in the United States in patients with Covid-19 infection requiring mechanical ventilation, announcing that adverse events.

The two health groups also explain that this trial did not meet its primary and secondary evaluation criteria when Kevzara was added to the best supportive care, compared to the best supportive care only (placebo).

However, they specify that a separate trial, piloted by Sanofi and based on a different dosage regimen, is currently being conducted outside the United States with patients hospitalized for a severe and critical form of Covid-19.



District officials felt socially disadvantaged

Meghan mom a second time? Harry confirmed that the second child is on his way!


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.